What is it? Why is it important?

A Risk-Based-Approach is a decision-making process that includes ways to identify, assess, manage, and control risks associated with an activity.

 

In studies, this relates to risks that threaten the integrity of study identified “Critical-to-Quality” (CtoQ) factors, such as the:

 

A Risk-Based-Approach means to:

  • Systematically identify CtoQ factors early during study planning, protocol development, and process mapping
  • Identify risks potentially able to threaten the CtoQ factors of the study
  • Assess the likelihood of risk occurrence, detectability, and expected impact on CtoQ factors
  • Prioritise risks, and define risk control-measures proportionate to risk significance.

 

A Risk-Based-Approach requires a “Quality-by-Design” (QbyD) approach. The aim is to manage risks before they occur, thereby providing credible and useful study results.

More

A risk-based approach means to:

  • Communicate, train and continuously engage staff and stakeholders on risk control-measures, with a clear understanding of roles and responsibilities
  • Continuously review and adapt risk control-measures for ongoing applicability and effectiveness
  • Document risk control-measures, their potential deviations and improvement in real time

 

Applying a risk-based approach provides the opportunity to focus on the most risk relevant tasks needed for study conduct.

What do I need to do?

As a SP-INV, familiarise yourself with how to identify Critical-to-Quality (CtoQ) factors, and how to identify and assess risks that threaten their integrity.

 

Assess how risks impact the:

 

As a Site-INV, support the SP-INV in the identification of risks to CtoQ factors that are applicable to the setting of the participating study site.

 

As a SP-INV, upon risk identification:

  • Focus on risks that occur as a result of study conduct (i.e. implementation of study processes and procedures)
  • Implement appropriate risk control-measures in accordance with level of risk
  • Invest resources in those areas where risks may have the greatest negative impact

More

Proactively identify the CtoQ factors of your study, including potential risks, early on during study planning. Use a Quality-by-Design (QbyD) approach throughout the trial lifecycle.

 

The Swiss law defines risks based on study risk category and type of intervention.

 

  • Example of risk categorisation in ClinO studies:
    • Medicinal product studies have risk categories A, B and C, with category C having the highest risk
    • Other clinical trial studies have risk categories A and B, with risk category B having the highest risk
  • Risks depend on target population, with consenting adults having the lowest risk compared to vulnerable populations:
    • Children and adolescents 
    • Participant without capacity
    • Participants in an emergency situation
  • Risks are assessed based on type of intervention, such as studies:
    • With or without expected direct benefit
    • With or without minimal risks and burdens

Depending on risk, the required risk management and its potential strategy within a given study can vary greatly.

 

Depending on risk, the required risk management and its potential strategy within a given study can vary greatly.

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular

  • 3.10 Quality Management

ICH E8(R1) for Quality by Design and Critical-to-Quality factors

ISO 31000 (access liable to costs) – see in particular section

  • Risk management: Principles and guidelines

Swiss Law

HRA – see in particular article and chapter

  • Art. 12 Risks and burdens
  • Chapter 3 Additional requirements for research involving vulnerable persons

ClinO – see in particular article

  • Art. 19 Categorisation of studies with medicinal products

Document

Abbreviations
  • ClinO – Clinical Trials Ordinance
  • CtoQ – Critical to Quality factors
  • CTU – Clinical Trials Unit
  • HRA – Human Research Ordinance
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ICH - International Council for Harmonisation
  • ISO – International Organization for Standardization
  • QbyD – Quality by Design
  • Site-INV – Site Investigator
  • SP-INV – Sponsor-Investigator
Basic ↦ Quality and Risk ↦ Risk-Based Approach to Quality ↦ Definition
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Basic ↦ Quality and Risk ↦ Risk-Based Approach to Quality ↦ Definition